MindMaze Therapeutics Holding SA (RLFTY)

Healthcare · OQB · US

$3.140.00% today

Price as at 1 Oct 2026, 00:35 UTC. Quotes are delayed.

Fundamentals

Market cap$533.78M
Revenue growth (YoY)+1731.3%
52-week range$0.27 to $4.05

Valuation and ratings

Moat score42/100
Overall rating46/100, moderate quality

MindMaze Therapeutics Holding SA trades at $3.14. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.

Our moat model scores it 42 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.

About MindMaze Therapeutics Holding SA

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Industry: BiotechnologyEmployees: 10HQ: Switzerland

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

RLFTY passes 2 of our 30 screens today

Each screen prints the exact criteria it used, and the circumstances in which it is wrong.

RLFTY peers

The largest companies in the same industry (Biotechnology), then in the same sector.

Every healthcare company we cover is on the Healthcare hub.

Common questions

Where does SteadyShares get its RLFTY data?

Fundamentals for RLFTY come from company filings and exchange data, as listed on OQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:35 UTC and is delayed. Our data quality score for this company is 67/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.

The full research page for RLFTY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.

Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.